Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.61 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056201 | 0.88 | PTPN1 (0.74) | PTPN1PTPN2 | |
| SCHEMBL3918247 | 0.82 | PTPN1 (0.70) | PTPN1ACMSDPTPN2ALOX5 | |
| SCHEMBL3221334 | 0.80 | PTPN1 (0.57) | PTPN1PTPN2CHEK1 | |
| SCHEMBL3920603 | 0.80 | PTPN1 (0.67) | PTPN1PTPN2 | |
| SCHEMBL3222925 | 0.79 | PTPN1 (0.65) | PTPN1PTPN2 | |
| SCHEMBL3918842 | 0.78 | PTPN1 (0.61) | PTPN1ERN1PTPN2CHEK1 | |
| SCHEMBL3214144 | 0.77 | PTPN1 (0.60) | PTPN1PTPN2CHEK1 | |
| SCHEMBL3926871 | 0.76 | PTPN1 (0.58) | PTPN1PTPN2 | |
| SCHEMBL3224416 | 0.76 | PTPN1 (0.58) | PTPN1PTPN2 | |
| SCHEMBL3928767 | 0.76 | ERN1 (0.40) | PTPN1ERN1ACMSDPTPRCCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | PTPN1 21/4885ERN1 3193/4885ACMSD 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.